Summary & Overview
HCPCS Level II C9148: Injection, teclistamab-cqyv, 0.5 mg
HCPCS Level II code C9148 denotes the administration unit for teclistamab-cqyv, a targeted injectable biologic dosed per 0.5 mg. As a drug-specific HCPCS Level II code, C9148 is used on outpatient and physician-administered drug claims to identify the product and support billing and reimbursement for this high-cost therapy. Nationally, accurate reporting of this code matters for drug utilization tracking, payment clarity, and patient cost-sharing calculations.
Key payers covered in this analysis include major national carriers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing benchmarks, and common administrative practices across these plans.
Readers will learn how C9148 is used in clinical billing workflows, typical sites of service for administering teclistamab-cqyv, and the types of benchmarks payers and providers monitor for high-cost injectable biologics. The report also summarizes relevant policy updates and documentation expectations that affect claim adjudication and reimbursement, and highlights areas where consistent coding supports program integrity and patient access. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9148 describes injection, teclistamab-cqyv, 0.5 mg. This code represents a specific parenteral biologic administration of teclistamab-cqyv dosed in 0.5 mg increments.
Service type: Injectable biologic therapy
Typical site of service: Outpatient infusion or injection clinic, hospital outpatient department, or physician office
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with relapsed/refractory multiple myeloma who has exhausted at least four prior lines of therapy presents for administration of bispecific T-cell engager immunotherapy. The therapy C9148 (injection, teclistamab-cqyv, 0.5 mg) is prepared in the clinic pharmacy and delivered via intravenous or subcutaneous route per product labeling and institutional protocol. The typical clinical workflow includes verification of patient identity and consent, review of recent laboratory tests (complete blood count, chemistry panel), assessment for active infections, baseline vital signs and performance status, premedication as indicated (e.g., antipyretic, antihistamine, corticosteroid), administration of the drug by an oncology nurse in an outpatient infusion center or hospital outpatient department, monitoring for infusion or injection-related reactions and cytokine release syndrome during and after dosing, and documentation of lot number, dose administered, route, and any adverse events. Follow-up includes scheduled monitoring visits, lab surveillance, and documentation of subsequent doses or dose modifications. Typical site of service: outpatient infusion center, hospital outpatient department, or specialized oncology clinic. Typical patient scenario: adults with relapsed/refractory multiple myeloma receiving a weight- or fixed-based dose of teclistamab as part of standard of care or a labeled therapy course.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |